Economic and Clinical Impact of Emicizumab in People With Moderate and Severe Hemophilia A in the US
Evolution of joint health and physical activity in people with hemophilia A without factor VIII inhibitors switching to emicizumab prophylaxis: A second interim analysis of the BEYOND ABR study
Real-World Treatment Patterns for Hemophilia A Since the Launch of Emicizumab in the US
RESHAPE: A non-interventional study of real-world treatment patterns and outcomes across age groups in people with severe hemophilia A in Latin America, Eastern Europe, Africa, Asia, and the Middle East
Exploratory analysis from HAVEN 1–4 to further contextualize injection-site reactions among people with hemophilia A receiving emicizumab
Emicizumab prophylaxis in pups and mtps with severe haemophilia: The pednet real world experience in 80 infants
Long-term outcomes with emicizumab prophylaxis in patients with hemophilia A in China
Real-world use of prophylaxis in people with non-severe hemophilia in the United States: Insights from the athn transcends Study - hemophilia natural history arm
Cardiovascular disease risk assessment in Japanese adults with hemophilia: Interim results of a multicenter study
Assessment of coagulation potential of concomitant factor VIII administration in patients with haemophilia A receiving emicizumab prophylaxis (CAGUYAMA Study): A multicenter, open-label, non-randomized clinical trial:
Rates of inhibitor development and immune tolerance in children with severe Hemophilia A on emicizumab prophylaxis
